Board of Directors

Liz Hewitt, Member of the board

Liz Hewitt, Member of the board

From 2004 to 2011 Ms Hewitt was Group Director Corporate Affairs for Smith & Nephew plc, UK, and was involved at a senior level in all aspects of the business, including membership of Risk Committee. At 3i Group plc, UK, 1986 to 2004, Ms Hewitt held a number of roles from investing and syndicating private equity transactions, to running the internal consultancy team, culminating in her role as Director Corporate Affairs, when she was a member of Risk Committee and a Trustee of the 3i Charitable Foundation. In her early career, Ms Hewitt qualified with Andersen & Co and also worked as a private equity investor for Citicorp Venture Capital (now CVC), UK and Gartmore Investment Management Ltd, UK.

Ms Hewitt serves as a member of the boards of Synergy Health plc, and Melrose Industries plc, both in UK. In Synergy Health plc she is also chair of the audit committee and a member of both the remuneration and nominations committees. Ms Hewitt is also an external member of the audit committee of the House of Lords, UK.

Ms Hewitt has a BSc (Econ Hons) from the University College in London, UK, from 1977, and became Chartered Accountant FCA in 1982. Ms Hewitt was first elected to the Board of Novo Nordisk A/S in 2012 and has most recently been re-elected in March 2014. Her term as a board member expires in March 2015.

In March 2014, the Board of Directors of Novo Nordisk A/S assessed that Ms Hewitt is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by NASDAQ OMX Copenhagen (2013).

Ms Hewitt became member of the Audit Committee at Novo Nordisk A/S in March 2012, and at the same time she was designated by the Board of Directors as financial expert under both Danish law and US Securities and Exchange Commission (the "SEC") rules. In March 2014, the Board of Directors of Novo Nordisk A/S assessed that Ms Hewitt is regarded as independent under SEC rules and is regarded as independent under part 8 of the Danish Act on Approved Auditors and Audit Firms.

Ms Hewitt became member of the Nomination Committee at Novo Nordisk A/S in April 2013.

In January 2014, the Board of Directors also assessed that the special competences possessed by Ms Hewitt that are important for the performance of her duties are her extensive experience within the field of medical devices, significant financial knowledge and knowledge about how large international companies operate.

Ms Hewitt is a female UK national, born November 1956.